81 related articles for article (PubMed ID: 19332708)
1. Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma treated with tyrosine kinase inhibitors?
Bamias A; Lainakis G; Manios E; Koroboki E; Karadimou A; Zakopoulos N; Dimopoulos MA
J Clin Oncol; 2009 May; 27(15):2567-9; author reply 2569-70. PubMed ID: 19332708
[No Abstract] [Full Text] [Related]
2. Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices.
Appleby L; Morrissey S; Bellmunt J; Rosenberg J
Hematol Oncol Clin North Am; 2011 Aug; 25(4):893-915. PubMed ID: 21763973
[TBL] [Abstract][Full Text] [Related]
3. Against: The case for cytoreductive nephrectomy for the management of metastatic renal cell carcinoma.
Carver BS
J Urol; 2009 Sep; 182(3):833-4. PubMed ID: 19616224
[No Abstract] [Full Text] [Related]
4. Update on the use of mTOR inhibitors in renal cell carcinoma.
Rini BI
Clin Adv Hematol Oncol; 2008 Oct; 6(10):722-4. PubMed ID: 18997660
[No Abstract] [Full Text] [Related]
5. Temsirolimus for advanced renal cell carcinoma.
Figlin RA
Clin Adv Hematol Oncol; 2007 Nov; 5(11):893. PubMed ID: 18185488
[No Abstract] [Full Text] [Related]
6. Hypertension Induced by Tyrosine-Kinase Inhibitors for the Treatment of Renal Cell Carcinoma in Hemodialysis Patients: A Single-Center Experience and Review of the Literature.
Nakai K; Fujii H; Kono K; Goto S; Nishi S
Ther Apher Dial; 2017 Aug; 21(4):320-325. PubMed ID: 28544682
[TBL] [Abstract][Full Text] [Related]
7. Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.
Jafri M; Douis H; Porfiri E
Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):657-8. PubMed ID: 18644704
[No Abstract] [Full Text] [Related]
8. Metastatic renal cell carcinoma to heart: cardiac surgery versus cardiotoxicity of kinase inhibitors.
Koniari I; Apostolakis E; Baikoussis NG
Interact Cardiovasc Thorac Surg; 2010 Dec; 11(6):816. PubMed ID: 21097460
[No Abstract] [Full Text] [Related]
9. Renal cell cancer: the unmet needs.
Durán I
Anticancer Drugs; 2011 Jan; 22 Suppl 1():S1-3. PubMed ID: 21173602
[No Abstract] [Full Text] [Related]
10. Treatable causes of diarrhoea in patients on tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Lightowlers SV; Greef B; Eisen T; Matakidou A; Fife K; Cameron EA
Ann Oncol; 2019 Jan; 30(1):150-151. PubMed ID: 30358823
[No Abstract] [Full Text] [Related]
11. [Resistance to tyrosine kinase inhibitors in renal cell carcinoma].
Miyake H; Fujisawa M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():331-5. PubMed ID: 23513861
[No Abstract] [Full Text] [Related]
12. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
Oudard S; Medioni J; Aylllon J; Barrascourt E; Elaidi RT; Balcaceres J; Scotte F
Expert Rev Anticancer Ther; 2009 Jun; 9(6):705-17. PubMed ID: 19496707
[TBL] [Abstract][Full Text] [Related]
13. Recent investigations of histone deacetylase inhibitors in renal cell carcinoma.
Pili R
Clin Adv Hematol Oncol; 2009 Apr; 7(4):252-4. PubMed ID: 19521328
[No Abstract] [Full Text] [Related]
14. Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma.
Shepard DR; Garcia JA
Expert Rev Anticancer Ther; 2009 Jun; 9(6):795-805. PubMed ID: 19496716
[TBL] [Abstract][Full Text] [Related]
15. [Management of toxicities due to anti-angiogenic treatment of metastatic renal carcinoma].
Méjean A; Lebret T
Prog Urol; 2008 Nov; 18 Suppl 7():S315-9. PubMed ID: 19070809
[TBL] [Abstract][Full Text] [Related]
16. New treatment approaches in renal cell carcinoma.
Facchini G; Perri F; Caraglia M; Pisano C; Striano S; Marra L; Fiore F; Aprea P; Pignata S; Iaffaioli RV
Anticancer Drugs; 2009 Nov; 20(10):893-900. PubMed ID: 19752718
[TBL] [Abstract][Full Text] [Related]
17. New therapies after failure of angiogenesis inhibitors.
Escudier B
Clin Adv Hematol Oncol; 2009 Aug; 7(8):512-4. PubMed ID: 19927977
[No Abstract] [Full Text] [Related]
18. Editorial comment.
Oya M
J Urol; 2009 Dec; 182(6):2577. PubMed ID: 19836782
[No Abstract] [Full Text] [Related]
19. [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].
Shuuin T; Karashima H
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1076-9. PubMed ID: 19620795
[TBL] [Abstract][Full Text] [Related]
20. [Renal cell carcinoma and antiangiogenic agents: ongoing controversies are seeking answers for improvement of therapeutic management].
Audenet F; Rouprêt M; Méjean A
Prog Urol; 2009 Oct; 19(9):596-605. PubMed ID: 19800548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
